Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.
about
Physiological and pathological phosphorylation of tau by Cdk5The role of tau in neurodegenerative diseases and its potential as a therapeutic targetTau and tauopathiesGenotype-specific differences between mouse CNS stem cell lines expressing frontotemporal dementia mutant or wild type human tauPhosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, p25, or p39Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells.Two-dimensional electrophoresis of tau mutants reveals specific phosphorylation pattern likely linked to early tau conformational changes.RNA stores tau reversibly in complex coacervatesA caspase cleaved form of tau is preferentially degraded through the autophagy pathway.Long- and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimer's miceThe frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner.Tumor suppressor PTEN affects tau phosphorylation: deficiency in the phosphatase activity of PTEN increases aggregation of an FTDP-17 mutant Tau.Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.Taxol and tau overexpression induced calpain-dependent degradation of the microtubule-destabilizing protein SCG10.New application of beta-galactosidase complementation to monitor tau self-association.Tau mutations in neurodegenerative diseases.Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration.The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule.Protein phosphorylation in neurodegeneration: friend or foe?Activation of glycogen synthase kinase 3beta promotes the intermolecular association of tau. The use of fluorescence resonance energy transfer microscopy.Tau aggregation and toxicity in a cell culture model of tauopathy.Cytosine beta-D-arabinofuranoside used as a paradigm modifier to increase production of tau aggregates in a cellular model of tauopathy.Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation.Mutant (R406W) human tau is hyperphosphorylated and does not efficiently bind microtubules in a neuronal cortical cell model.Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function.Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites.Quantitative and combinatory determination of in situ phosphorylation of tau and its FTDP-17 mutants.Concentration-dependent effects of proteasomal inhibition on tau processing in a cellular model of tauopathy.Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast.Lentiviral delivery of the human wild-type tau protein mediates a slow and progressive neurodegenerative tau pathology in the rat brain.A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations In Vivo.Mutant protein kinase Cgamma found in spinocerebellar ataxia type 14 is susceptible to aggregation and causes cell death.Tau gene mutations and their effects.Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
P2860
Q26860395-CB512CBE-8C94-46AD-8C1C-28B3F52D0A82Q27005032-42EF24BA-275C-4CE7-8657-9061CC8B803EQ27027415-0728E7D3-2472-49D8-8253-200C0576F65EQ28480475-4CEABC91-BED8-475C-889E-172ECF949508Q28574229-B14CE12A-F468-4E09-9045-C8C7D2BD2E2AQ31125501-7C676DBB-2884-4A40-8C8C-CA356E584FDFQ33418581-678B4970-A47D-4A3B-9ED0-2851A17B7D46Q33879490-4F3302AD-2039-4FC4-878B-1FE3E8409971Q33991036-61B03DFF-E095-427D-A1ED-EB0B06CD71C0Q34159111-F959F4A8-CC23-4DFA-9546-F238594CFD21Q34600755-3942618B-1987-4B07-99B6-664641065FE4Q35016068-B836D72A-573D-4B03-A262-A81E0422E24FQ36916967-2A0C3FF2-BA75-4A7C-9254-84D6AC2D045FQ36966635-E697BF6D-4A69-4025-9C81-CA82A535D339Q37148063-F9B9D45B-AD15-45EE-9CB3-C76DC9806516Q37307240-EEAA58BF-1B22-4437-828B-D201127D2EEFQ37362099-3A9A03C5-F796-45FA-BC9B-97ED4326EB43Q37401466-1E3782CA-F435-4178-BC7A-C05E84AF5917Q38214594-7E3868D4-DAF9-4D98-A365-939003524A12Q40120481-424DB35D-F0CD-4CDD-AAF0-12F8DA6F3321Q40146754-E725A26E-00E7-42DB-A210-D62510BEEE10Q40199573-2C448D3D-5115-4F03-BD02-B961E6753670Q40281556-E0C9A6E7-5B74-4CA4-BFBB-BF7C6846F317Q40609881-6847C6D5-4A17-4632-B662-6ACE6947A93EQ40658225-5F4124D6-B347-4B21-9FEA-F88BFB1046EBQ41115192-C6F9F8BE-09B7-4A2F-B843-4FFE5576AA02Q41117848-18EBE5DF-EC24-4D63-825F-F370259081CAQ41854251-4D88A267-D408-448F-9F51-F20D8031CA51Q42956203-E130B30C-E075-4FA6-ABD9-7E76D9E4A2F8Q43105468-16B2AF9E-B4BA-4883-B785-A9E8A366EF36Q47402222-8F07E227-E34A-4004-A21A-ADCE8BFA342EQ50764411-F1694B0B-D7BC-443C-8C97-A56080E7FAC5Q53373043-5F97A28B-7B9B-488A-8D62-0E62DAA6216AQ55248848-D1C60748-3F12-42E9-A681-17A3690AC382
P2860
Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.
@ast
Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.
@en
type
label
Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.
@ast
Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.
@en
prefLabel
Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.
@ast
Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.
@en
P2093
P2860
P1476
Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.
@en
P2093
Colin Easson
Michael DeTure
Shu-Hui Yen
P2860
P304
P356
10.1016/S0002-9440(10)64448-3
P407
P577
2002-11-01T00:00:00Z